Day: July 31, 2025

PolTREG and U.S. Subsidiary Immuthera Secure Positive FDA Opinion, Paving the Way for a Registrational Pre-Symptomatic Type 1 Diabetes TrialFDA agreed that PolTREG’s clinical data in Stage 3 Type 1 Diabetes (T1D) appears sufficient to support the Prospect of Direct benefit in an adaptive Phase 2/3 study of PTG-007 in Stage 1 and Stage 2 Presymptomatic T1D patients. The FDA is receptive to the inclusion of Stage 1 Polish patients in the trial’s statistical analyses FDA may consider the adaptive Phase 2/3 study as registrational, potentially expediting U.S. approval for PTG-007 in presymptomatic Type 1 diabetes. PolTREG and Immuthera will apply for Fast Track, Breakthrough, or Regenerative Medicine Advanced Therapy (RMAT) designation in the IND filing.31 July 2025 – PolTREG S.A. (Warsaw Stock Exchange: PTG), a pioneer in cell therapies...

July 31st, 2025 RCI Banque: ‘’2025 First Half Business Report’’ The RCI Banque group ‘’2025 First Half Business Report’’ is now available on the Mobilize Financial Services website www.mobilize-fs.comAttachmentRCI_MOBILIZE_RA_30_juin_2025_EN_MEL_25_07_31

   PRESS RELEASE  Paris, 31st July 2025     2025 FIRST HALF RESULTS :MOBILIZE FINANCIAL SERVICES DELIVERS SOLID GROWTH Mobilize Financial Services records a progression in new financing by 3.8% in the first semester of 2025 compared to the same period in 2024. This performance reflects a rise in the average amount financed and the commercial dynamics of Renault Group’s brands, Nissan and Mitsubishi, supported by a robust growth in registrations. With a progression of pre-tax profit by 9.7%, Mobilize Financial Services confirms the relevance of its strategy and its commitment to more sustainable mobility, in line with new uses. This performance confirms Mobilize Financial Services’ ability to efficiently support the strategy of its automotive partners, while meeting the expectations of customers in quest of flexible and...

Access the “What This Means” segment here LA JOLLA, CA, July 31, 2025 (GLOBE NEWSWIRE) — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it participated in a Virtual Investor “What This Means” segment. For the segment, Marc Hertz, PhD, President, Chief Executive Officer and Director of GRI, discussed the Company’s recently announced 6-week interim biomarker data from its ongoing Phase 2a study in Idiopathic Pulmonary Fibrosis (“IPF”). The “What This Means” segment can be accessed here. About GRI Bio, Inc. GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune...

Total income rose nearly 19% to €64.8 million, while operating income grew by 6.1% to €45.8 million The Marketing and Corporate Affairs firm updates its financial guidance for 2025 LLYC remains focused on growth and protecting profitability amid global uncertainty and delayed investmentsMADRID, July 31, 2025 (GLOBE NEWSWIRE) — LLYC (BME:LLYC) closed the first half of 2025 with a 15% increase in recurring EBITDA, reaching €7.9 million. According to the preliminary results — pending final audit — the Marketing and Corporate Affairs firm recorded €45.8 million in operating income, a 6.1% increase compared to the same period last year. Total income (which includes client service rebilling) grew by 18.9%, reaching €64.8 million. “The first-half results underscore our ongoing commitment to growth and protecting profitability amid...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OR THE DISTRICT OF COLUMBIA. TORONTO, July 31, 2025 (GLOBE NEWSWIRE) — Revival Gold Inc. (TSXV: RVG) (“Revival Gold” or the “Company”) is pleased to announce that it has closed its previously announced financing of common shares (the “Common Shares”) for total gross proceeds of approximately C$29.08 million (the “Offerings”). The Offerings were comprised of a strategic non-brokered private placement with EMR Capital Management Limited (“EMR”) pursuant to which EMR subscribed for 32,069,531 Common Shares at a price of C$0.48 per Common Share for gross proceeds of US$11.3 million (C$15.4 million) (the “EMR Placement”),...

A Media Snippet accompanying this announcement is available by clicking on this link. LONDON, July 31, 2025 (GLOBE NEWSWIRE) — SEGG Media Corporation (NASDAQ: SEGG, LTRYW) (“SEGG Media” or the “Company”), a leading technology company owning Sports.com, Concerts.com, and Lottery.com, today announced the launch of the Quadrant Speedway Collection. The collection is the brand’s first major apparel drop since SEGG Media’s strategic investment into Veloce Media Group (“Veloce”) and Veloce’s acquisition of Quadrant, the creator-led motorsport and lifestyle brand co-founded by Formula 1 driver Lando Norris. The Speedway Collection marks a high-impact activation of SEGG Media’s strategic investments in next-generation sports and entertainment platforms. The drop blends motorsport heritage with streetwear aesthetics. The collection was...

Viridien Société Anonyme with a share capital of €7,180,449Registered office: 27 avenue Carnot, 91300 MassyNo.: 969 202 241 – RCS Evry 2025 Interim Financial Report available Paris, France – July 31, 2025 Viridien announced that its interim financial report as at June 30, 2025 was filed today with the Autorité des Marchés Financiers (AMF). This document is available on the Company’s website: https://www.viridiengroup.com/ under the Investors section (both in “Regulated information” and “Results and Publications”). About Viridien: Viridien (www.viridiengroup.com) is an advanced technology, digital and Earth data company that pushes the boundaries of science for a more prosperous and sustainable future. With our ingenuity, drive and deep curiosity we discover new insights, innovations, and solutions that efficiently and responsibly resolve...

  Press Release  Paris – July 31, 2025 – EUROAPI posted today its 2025 condensed Half-Year Consolidated Financial Statements for the six months ended June 30, 2025. This document is available for consultation and downloading on EUROAPI’s website: https://www.euroapi.com/en/investors/regulatory-information/financial-reports.  This report includes notably the 2025 half-year management report, the consolidated financial statements on 30 June 2025, and the Statutory Auditors’ review report on the half-yearly financial information.  Financial agenda (all dates to be confirmed) 3 March 2026: FY 2025 Results  27 May 2026: 2026 AGM  28 July 2026: H1 2026 results About EUROAPI EUROAPI is focused on reinventing active ingredient solutions to sustainably meet customers’ and patients’ needs around the world. We are a leading player in...